2021 Clinical Trials Media Safety 
Cannabis Law Report
DECEMBER 9, 2021
The Financing is expected to close on December 10, 2021. The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch.
Cannabis Law Report
AUGUST 12, 2021
Net loss for the six months ended 30 June 2021 was $30.2 Net loss for the six months ended 30 June 2021 was $30.2 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
OCTOBER 15, 2021
At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Presentations at ASN Kidney Week 2021, November 4-7, 2021.
Project CBD
FEBRUARY 28, 2023
HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.) 2 The seeds of C.
Cannabis Law Report
OCTOBER 29, 2021
(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The primary endpoint of this Phase 1 trial was safety and tolerability. During the six months ended September 30, 2021, the Company raised approximately $4.1
Cannabis Law Report
AUGUST 3, 2021
The Shares were offered in each of the provinces of Canada, excluding Québec, pursuant to a prospectus supplement to the Company’s short form base shelf prospectus dated July 5, 2021. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products.
Cannabis Law Report
JULY 8, 2021
Enveric Enters into Clinical Stage Development of Lead Asset, EV101, in Israel with MOH Approval. We are targeting the fourth quarter of 2021 for the enrollment of our first patient, following the conclusion of the final study agreements with the site.” ” This product is not approved for marketing anywhere in the world.
Expert insights. Personalized for you.
52 
Let's personalize your content